CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade letter

Nature Medicine

Volumn 24, Issue 6, 2018, Pages 731-738

  Giavridis, Theodoros ^a   Van Der Stegen, Sjoukje J C ^a   Eyquem, Justin ^a   Hamieh, Mohamad ^a   Piersigilli, Alessandra ^b   Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; NITRIC OXIDE; CYTOKINE; INTERLEUKIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DISEASE SEVERITY; FEMALE; IMMUNOMODULATION; LETHALITY; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RECEPTOR BLOCKING; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; HUMAN; IMMUNOLOGY; MACROPHAGE; METABOLISM; NEOPLASM; PATHOLOGY; SYNDROME;

ANIMALS; CYTOKINES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MACROPHAGES; MICE; MYELOID CELLS; NEOPLASMS; SYNDROME;

EID: 85047803079     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-018-0041-7     Document Type: Article

References (44)

1. Sadelain, M., Rivière, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423-431 (2017).
2. Davila, M. L.,et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).
3. Maude, S. L.,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014).
4. Park, J. H.,et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449-459 (2018).
5. Barrett, D. M., Teachey, D. T. & Grupp, S. A. Toxicity management for patients receiving novel T-cell engaging therapies. Curr. Opin. Pediatr. 26, 43-49 (2014).
6. Bonifant, C. L., Jackson, H. J., Brentjens, R. J. & Curran, K. J. Toxicity and management in CAR T-cell therapy. Mol. Ther. Oncolytics 3, 16011 (2016).
7. Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 3321-3330 (2016).
8. Oluwole, O. O. & Davila, M. L. At the bedside: clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies. J. Leukoc. Biol. 100, 1265-1272 (2016).
9. Neelapu, S. S.,et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47-62 (2018).
10. Lee, D. W.,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 doseescalation trial. Lancet 385, 517-528 (2015).
11. Teachey, D. T.,et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664-679 (2016).
12. Hay, K. A.,et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130, 2295-2306 (2017).
13. Cray, C., Zaias, J. & Altman, N. H. Acute phase response in animals: a review. Comp. Med. 59, 517-526 (2009).
14. Meek, R. L., Eriksen, N. & Benditt, E. P. Murine serum amyloid A3 is a high density apolipoprotein and is secreted by macrophages. Proc. Natl Acad. Sci. USA 89, 7949-7952 (1992).
15. Vandevelde, M., Higgins, R. & Overmann A. Veterinary Neuropathology: Essentials of Theory and Practice. in Veterinary Neuropathology: Essentials of Theory and Practice 29 (Wiley, Hoboken, NJ, USA, 2012).
16. Gust, J.,et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404-1419 (2017).
17. Rincon, M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol. 33, 571-577 (2012).
18. Quezada, S. A., Jarvinen, L. Z., Lind, E. F. & Noelle, R. J. CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 22, 307-328 (2004).
19. Bossen, C.,et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J. Biol. Chem. 281, 13964-13971 (2006).
20. Tucker, T. A. & Schwiebert, L. M. CD40 ligation decreases its protein half-life at the cell surface. Eur. J. Immunol. 38, 864-869 (2008).
21. Wang, H.,et al. A novel role of the scaffolding protein JLP in tuning CD40-induced activation of dendritic cells. Immunobiology 218, 835-843 (2013).
22. Wang, H. M.,et al. Scaffold protein JLP is critical for CD40 signaling in B lymphocytes. J. Biol. Chem. 290, 5256-5266 (2015).
23. Elgueta, R.,et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229, 152-172 (2009).
24. Murray, P. J. & Wynn, T. A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11, 723-737 (2011).
25. Ohashi, Y.,et al. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J. Clin. Invest. 102, 2061-2071 (1998).
26. Titheradge, M. A. Nitric oxide in septic shock. Biochim. Biophys. Acta 1411, 437-455 (1999).
27. Moore, W. M.,et al. L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J. Med. Chem. 37, 3886-3888 (1994).
28. Garvey, E. P.,et al. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J. Biol. Chem. 272, 4959-4963 (1997).
29. Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519-550 (2009).
30. Saini, A. S., Shenoy, G. N., Rath, S., Bal, V. & George, A. Inducible nitric oxide synthase is a major intermediate in signaling pathways for the survival of plasma cells. Nat. Immunol. 15, 275-282 (2014).
31. Sims, J. E. & Smith, D. E. The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 10, 89-102 (2010).
32. Zhao, Z.,et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415-428 (2015).
33. van der Stegen, S. J.,et al. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity? J. Immunol. 191, 4589-4598 (2013).
34. Dinarello, C. A., Simon, A. & van der Meer, J. W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11, 633-652 (2012).
35. Shultz, L. D.,et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 154, 180-191 (1995).
36. Serreze, D. V., Gaedeke, J. W. & Leiter, E. H. Hematopoietic stem-cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C. Proc. Natl Acad. Sci. USA 90, 9625-9629 (1993).
37. Ohteki, T., Suzue, K., Maki, C., Ota, T. & Koyasu, S. Critical role of IL-15-IL-15R for antigen-presenting cell functions in the innate immune response. Nat. Immunol. 2, 1138-1143 (2001).
38. Gutierrez, E. G., Banks, W. A. & Kastin, A. J. Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier. J. Neuroimmunol. 55, 153-160 (1994).
39. Liu, J., Zhao, M. L., Brosnan, C. F. & Lee, S. C. Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-1 and IL-1 receptor antagonist. J. Immunol. 157, 3569-3576 (1996).
40. Tarassishin, L., Suh, H. S. & Lee, S. C. LPS and IL-1 differentially activate mouse and human astrocytes: role of CD14. Glia 62, 999-1013 (2014).
41. Gade, T. P.,et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 65, 9080-9088 (2005).
42. Maher, J., Brentjens, R. J., Gunset, G., Rivière, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR /CD28 receptor. Nat. Biotechnol. 20, 70-75 (2002).
43. Rivière, I., Brose, K. & Mulligan, R. C. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl Acad. Sci. USA 92, 6733-6737 (1995).
44. Gong, M. C.,et al. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1, 123-127 (1999).